Summary Primary carcinomas from 46 patients were screened for TP53 alterations. Immunohistochemistry demonstrated nuclear TPS3 protein accumulation in 22 (48%) cases using the polyclonal CM1 antiserum, whereas 15 (33%) cases showed positive nuclear staining with the mononuclear antibody PAb 1801. Constant denaturant gel electrophoresis (CDGE) was used to screen 27 of the vaginal carcinomas for mutations in the conserved regions of the TP53 gene (exons 5-8 (Lane and Benchimol, 1990). Although the precise mechanism by which the TP53 protein participates in these cellular functions is not fully understood, several biochemical features of TP53 have been elucidated. The TP53 protein is able to regulate transcription directly (Kern et al., 1991; El-Deiry et al., 1992) or by interacting with other transcriptional regulatory factors, such as the TATA-and CAAT-binding proteins (Seto et al., 1992; Agoff et al., 1993) . The TP53 protein has also been shown to act as a specific transcription factor controlling the expression of growth arrest genes such as GADD45 (Kastan et al., 1992) and WAF-I (El-Deiry et al., 1993).
The TP53 tumour-suppressor gene, which encodes a 53 kDa cell cycle regulator nuclear phosphoprotein, is located on the short arm of chromosome 17. The product of this gene has been implicated in the control of the cell cycle, DNA repair and synthesis, cell differentiation and programmed cell death (Harris and Hollstein, 1993) . Some mutant forms of the gene can act as dominant oncogenes, whereas wild-type TP53 has characteristics of a recessive tumour-suppressor gene (Lane and Benchimol, 1990) . Although the precise mechanism by which the TP53 protein participates in these cellular functions is not fully understood, several biochemical features of TP53 have been elucidated. The TP53 protein is able to regulate transcription directly (Kern et al., 1991; El-Deiry et al., 1992) or by interacting with other transcriptional regulatory factors, such as the TATA-and CAAT-binding proteins (Seto et al., 1992; Agoff et al., 1993) . The TP53 protein has also been shown to act as a specific transcription factor controlling the expression of growth arrest genes such as GADD45 (Kastan et al., 1992) and WAF-I (El-Deiry et al., 1993) .
Mutations in the TP53 gene are the most frequent genetic alteration found in human tumours (Hollstein et al., 1994; Levine et al., 1994) . The ability to transactivate gene expression from a specific promoter sequence is lost in most TP53 mutants associated with cell transformation and oncogenesis (Kern et al., 1991) . The mutations are usually missense and are frequently accompanied by loss of the remaining normal allele. Furthermore, mutated proteins are able to bind and activate wild-type TP53 protein by forming oligomeric complexes (Nigro et al., 1989) . Point mutations in the TP53 gene often result in increased stability of the mutant protein (Finlay et al., 1988) , which can be detected by immunohistochemistry, whereas the wild-type TP53 protein is undetectable because of its short half-life (Gronstajaski et al., 1984) . However, under certain circumstances accumulation of wildtype TP53 protein may occur, probably because of complex formation with other cellular proteins such as MDM2 , or virus proteins like the large T antigen of SV40 (Lane and Crawford, 1979) .
There is increasing evidence that tumour-suppressor genes are involved in the development and/or progression of gynaecological malignancies. Mutations or loss of heterozygosity at the TP53 locus have been reported in ovarian (Bosari et al., 1993; Kohler et al., 1993a) (Kohler et al., 1993b; Yu et al., 1993) and cervical cancers (Helland et al., 1993; Holm et al., 1993 (90s) and 72-C (120 s). The reaction was initiated with one 7-mm incubation at 94-C and ended with 10 min incubation at 72C, 4 min incubation at 94-C and 60 m incubation at 65YC. PCR products were analysed for purity on a 7.5% polyacrylamide gel. Samples giving a low yield of PCR product were usually reamplified using the PCR product as a template.
The four amplified products from each tumour were screened for TP53 mutations using constant denaturant gel eectrophoresis (CDGE) (Borresen et al., 1991; Hovig et al., 1991 The gels, which had the same chemicals and ekctrophoresis conditions as the constant denaturing gels, were run for 2 h with the gradient spanning from 10% to 70% denaturant. Gradient gels were stained and photographed usng both ethidium bromide, as described above, and SYBR green I (Molkuar Probes, Eugene, OR, USA) diluted 1:10000. Samples that carried a mutation were amplified with one biotinylated primer. The PCR products were sequenced with dideoxy sequencing reactions using Dynabeads M280-Strptavidin (DynaL Norway) as solid support (Hultman et at., 1989) . Oligonucleotides flaning each of exons 5, 7 and 8 were used to prime the reactions, which were performed by first heating the primer-template mix (70 C). Then the samples were labeLlld for 10 min with [3SJdCTP, and the termination reactions were run with Sequenase 2.0 17 DNA polymerase (US Biochemicals) at 3TC for 10 min. The reaction products were electrophoresed on a 4.3% polyacrylamide gel, which was dried and autoradiographed with Kodak Hyperfilm-MP beta-max overnight.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue specimens from 46 cases were used for munhistochemical staining with the avidin-biotin-peroxidase complex (ABC) method (Hsu et al., 1981) . Deparaffinised sections were treated with 0.3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase. The sections were incubated for 20min with normal serum from the species in which the secondary antibody was made. This was done to eliminate non-specific staining. Excess normal serum was blotted from the slides before incubation with a polyclonal TP53 antiserm (NCL-CM1, Novocastra Laboratory, UK) diluted 1:300 and a monoclonal TP53 antibody (PAb 1801, Oncogene Science, NY, USA) diluted 1:100 (1 Mg of IgG, per ml) for 18-22 h at 4C. Both antibodies detete mutant and wild-type TP53. The sections were then incubated with a 1:200 dilution of biotin-labeled secondary antibody for 30min and ABC (10 igml-' avidin and 2.4 jgml ' biotinlabelled peroxidase) (Vector, Burlingame, CA, USA) for 60min. The tissue was stained for 5min with 0.05% 3,3'-diaminobenzidine tetrahydrochloride (DAB) freshly prepred in 0.05 M Tris buffer at pH 7.6 containing 0.01% hydrogen peroxide. Sections were then countetained with haematoxyfin, dehydrated and mounted in Diatex. All the dilutions of normal sera, antisera, biotin-labeiled secondary antibodies and ABC were done with phosphate-buffered saline (PBS), pH 7.4, containing 5% bovine serum a in All series incuded positive controls Negative controls included replcement of polyclonal prmary antisrum with rabbit serun diluted 1:300, whereas negative controls for the monoclonal antibody were performed usng mouse myeloma protein of the same subclass and concentration as the monoclonal antibody. All controls gave satisfactory results.
Statistical analysis
Differences in proportion were evaluated by the chi-square test Cancer-related survival was lalcted from start of treatment to death of diseas, or 31 May 1994, usng the method of Kaplan and Meier (1958) . Diffaences in surival were evaluated usng the log-rani test (Tarone and Ware, 1977) . A P-ievel less than 0.05 was conidere atistically signifiCant.
Rests TP53 mutation analysis Of the 46 samples that were subjected to immunotaining, sUffiCient material for CDGE and DGGE analyses were available for 27 samples. Six (22%) of these tumours contained mutations: four were identified in exon 5 and two in exon 8 ( al., 1992; Helland et al., 1993) . In vaginal carcinomas we did not find an inverse relationship between HPV DNA and TP53 alterations. In 11 of 14 cases with TP53 alteration, HPV 16 was also detected (unpublished findings).
In the present study there was a 70% correlation between mutation and immunohistochemical data. This is in contrast to earlier studies in which a highly signnt association between the presence of TP53 mutations and TP53 protein accumulation was observed (Andersen et al., 1993; Marchetti et al., 1993) . In previous studies, an increasing number of tumours with TP53 protein accumulation without altered DNA have been found (Helland et al., 1993; Lae, 1994 (Andersen and Borresen, 1995 (Hall et al., 1993; Fritsche et al., 1993 al., 1992) . In one of the mutated samples we failed to find a positive immunoreaction. A mutation implying a shift in reading frame or a stop codon could lead to a change in a large proportion of the quatemary structure of the protein which would result in the absnce of TP53 immunostaining (Andersen and Borresen, 1995) . Lack of immunostaining could also be explained by the presence of a sense mutation that does not stabilise the protein sufficiently.
CDGE and DGGE analysis identified TP53 gene mutations in six of 27 (22%) vaginal carcinomas. We were able to determine the exact nature of the mutation by direct sequencing only in the DNA extracted from the fresh-frozen tissue. This method required more template DNA and PCR product than CDGE and DGGE analysis. The sequencing prims were different from the CDGE and DGGE primers. It is therefore possible that formalin fixation had degraded or modified the DNA in a way that disturbed anling of the sequencng primers or, alternatively, the chain elongation. The amount of tissue from each sample was scarce, and thus sequencing would most likely be more successful when done on a largr amount of tissue. Previously, the CDGE/DGGE technique has proved to be highly rehable, with a detection rate of 100% of mutants in exon 5, 7 and 8 under optimal conditions (Condie, 1993) . All samples with aberrant migrating bands in DGGE displayed heteroduplex formation. The heteroduplexes that are easily recognised in melting gels enable detection of mutations when present in 1-5% of the cell population (Andersen and Borresen, 1995) .
Numerous antibodies detecting TP53 protein are available. We observed positive immunoreactivity more often with the polydonal antiserum CM1 than with the monoclonal antibody PAb 1801. This discrepancy may be due to aceumulation of TP53 protein with a configuration detted by the polyclonal but not the monoclonal antibody. In addition, the failure of PAb 1801 to detect TP53 protein in some specmens immunoreactive with CM1 could be because the epitope recognised by PAb 1801 antibody is not stable in formalin-fixed tissu (Purdie et al., 1991) .
No correlation was ssen between TP53 alteration and survival of patients with vaginal carcinomas. This is in agreement with other studies that fail to find prognostic significae in cancers of the ovary (Marks et al., 1992; Kohler et al., 1993a) and cervix (Helland et al., 1993; Oka et a!., 1993) . In contrast, other groups of investigators observed a relationship between behaviour and TP53 alteration in cancers of the ovary (Bosari et al., 1993) and endometrium (Bur et al., 1992) . Our study inluded a limited number of cases, and therefore further studies of a largr amount of material are needed to better define the prognostic significae of TP53 alterations in patients with vaginal cancer.
In conclusion, TP53 alterations were dedtet in 50% of primary vaginal carcinomas by use of genetic and immunohistochemical techniques. These results indicate that TP53 abnormalities may be involved in the development of these tumours. However, there was no signnt correlation between TP53 alteration and survival.
